Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What does the future hold for cell-based tolerogenic therapy?

Jeffrey A Bluestone1, Angus W Thomson, Ethan M Shevach

  • 1Immune Tolerance Network and of the Diabetes Center at the University of California, USA.

Nature Reviews. Immunology
|July 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generation of Regulatory Dendritic Cells From Living Donor Liver Transplant Perfusates.

Transplantation·2026
Same author

Protocol for identifying recirculating thymic regulatory T cells and characterizing the role of Eos in their function using scRNA-seq and TCR-seq.

STAR protocols·2026
Same author

Antibody Blockade of Ly49/MHC-I interactions enhances Innate and Adaptive Immunity Against Cancer Metastasis.

bioRxiv : the preprint server for biology·2026
Same author

Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.

Nature communications·2026
Same author

Peri-transplant interleukin-6 receptor blockade delays acute cellular rejection and significantly prolongs kidney allograft survival in tacrolimus/CTLA4Ig-treated nonhuman primates.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Innovative approaches targeting innate immune cells to promote organ transplant tolerance.

Frontiers in transplantation·2026

Cell-based tolerogenic therapy shows promise for treating transplant rejection and autoimmune diseases. Further research is needed to address key issues before human application of regulatory T cells and tolerogenic dendritic cells.

Area of Science:

  • Immunology
  • Cell therapy
  • Transplantation immunology

Background:

  • Animal models demonstrate that regulatory T cells (Tregs) and tolerogenic dendritic cells (tDCs) can prevent transplant rejection and autoimmune diseases.
  • T-cell-mediated diseases represent a significant clinical challenge.
  • Cellular therapies offer a potential avenue for re-establishing self-tolerance.

Approach:

  • This review synthesizes expert opinions from four leading researchers in the field.
  • It highlights critical considerations for advancing cell-based tolerogenic therapy.
  • The focus is on the future potential and challenges of immunotherapy.

Key Points:

  • Regulatory T cells and tolerogenic dendritic cells are key cellular components for inducing tolerance.

Related Experiment Videos

  • Translating these findings from animal models to human therapies requires careful consideration.
  • The development of effective and safe cell-based tolerogenic treatments is an active area of research.

    • Conclusions:

    • Cell-based tolerogenic therapy holds significant potential for treating immune-mediated diseases.
    • Addressing specific challenges is crucial for clinical translation.
    • Future research should focus on optimizing cell therapies for human application.